Advanced search in Research products
Research products
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
Include:
The following results are related to COVID-19. Are you interested to view more results? Visit OpenAIRE - Explore.
433 Research products, page 1 of 44

  • COVID-19
  • Publications
  • Research data
  • Other research products
  • Other ORP type
  • ZENODO
  • COVID-19

10
arrow_drop_down
Relevance
arrow_drop_down
  • Open Access
    Authors: 
    Dinar Duarte Vasconcelos;
    Publisher: Zenodo

    Atividade interativa sobre Saúde Planetária e Covid-19, desenvolvida com fins didáticos pedagógicos para adolescentes de escola pública. A educação é uma aliada no combate a pandemia da Covid-19. Espaços formais como as escolas deveriam ser utilizadas com o objetivo de combater fake news, proporcionar conhecimento acadêmico sobre doenças infecciosas entres adolescentes. A aprendizagem precisa ser significativa e contextualizada, estimular os jovens a assumirem papel de protagonismo juvenil. Para isso, utilizar tecnologias visando a construção de espaços para abordar temas complexos e necessários.

  • Open Access English
    Authors: 
    Hayder Fawzi; Haydar Al-Tukmagi;
    Publisher: Zenodo

    examination of pharmacy students

  • Open Access French
    Authors: 
    GEBEIL Sophie; FELIX Christine; FILIPPI Pierre-Alain; MARTIN Perrine;
    Publisher: Zenodo

    Le questionnaire a été diffusé en ligne du 9 avril 2020 au 7 juin 2020 sur http://sphinx2.espe.univ-amu.fr/v4/s/9ab5go Il a recueilli 4071 réponses.

  • Open Access
    Authors: 
    Setayesh Yazdani; Nicola De Maio; Matthieu Schapira;
    Publisher: Zenodo

    This document is about the druggability and genetic variability of the ADP-bound pocket of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) NiRAN domain across coronaviruses and SARS-CoV-2 samples. This report also accompanies this post on https://openlabnotebooks.org/.

  • Other research product . Other ORP type . 2021
    Open Access
    Authors: 
    Wallace Claire; Shaddock John;
    Publisher: Zenodo
    Project: EC | SPOT (870644), EC | SPOT (870644)

    Purpose and scope of the deliverable: This is a framework report on Policies, Practices and Strategies. All partners have contributed material used in the production of the report which is described in the Work Programme as D2.1. This report seeks to establish a benchmark. With so much in flux, a starting point for identifying sig-nificant policy change is necessary. The benchmark is set at the outset of the project, approximately Q1 (January to March 2020), before the impact of COVID-19 and before the onset/impact of the new Programming Period. As a benchmark, the report seeks to be descriptive; there is no attempt at this stage to introduce any evaluation into the document; nor is there an intention to ’cluster’ case studies or countries – each case stands on its own merit. The attention to policy detail at Case Study level is relatively light. Here we are describing the Policy Framework. Detailed work on the Case Studies will take place later in the project when we have access to survey data and can view the emerging policies following the current hiatus in tourism. This is the first stage of the policy theme running through the three years of SPOT - the Social and Innovative Platform on Cultural Tourism and its Potential towards Deepening Europeanisation. This Framework Paper consists of four parts: Part One: The Executive Summary Part Two: The report on Policies, Practices and Strategies for each of the 15 partners (= Appendix A – Exploration of the Policy Framework) Part Three: A spreadsheet showing broad themes for each of the partners (= Appendix B) Part Four: A list of the sources used in preparing the report

  • Open Access
    Authors: 
    J. E. Pekar; J. O. Wertheim;
    Publisher: Zenodo

    Data 5 for the manuscript. Refer to Data 1 for the full description and links to the remaining datasets: https://doi.org/10.5281/zenodo.6887186

  • Open Access
    Authors: 
    Matthew Koster1;
    Publisher: Zenodo

    Background: Pre-clinical giant cell arteritis (GCA) mouse models have demonstrated effective suppression of arterial wall lesional T-cells through inhibition of Janus kinase 3 (JAK3) and JAK1. However, JAK inhibition in patients with GCA has not been formerly investigated. Methods: We performed a prospective, open-label, pilot study of baricitinib (4mg/day) in patients with relapsing GCA. The primary outcome was the frequency of adverse events and serious adverse events at week 52. Secondary outcomes included relapse at week 24 and week 52, change in pre-enrollment erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) to week 24 and week 52, and comparison of glucocorticoid dose at enrollment to week 24 and week 52. The study schema is outlined in Figure 1. Results: 15 patients were enrolled in the study (11, 73% female) with a mean(SD) age at entry 72.4(7.2) years, median(IQR) duration of GCA of 9 (7, 21) months, and median of 1 (1, 2) prior relapse. Treatments prior to study entry included: glucocorticoids (15, 100%); methotrexate (2, 13%); cyclophosphamide (1, 7%); sirukumab (1, 7%). Characteristics at GCA diagnosis and at relapse prior to study entry are listed in Table 1. Four (27%) patients entered the study on prednisone 30mg/day, 6 (40%) at 20 mg/day, and 5 (33%) at 10mg/day. One patient with baseline chronic kidney disease had a decline in renal function below study threshold for continuation and was withdrawn at week 8. The remaining 14 patients completed 52 weeks of baricitinib. At week 52, 14/15 (93%) patients had at least one adverse event recorded with the most frequent events including: infection not requiring antibiotics (n=8), infection requiring antibiotics (n=5), nausea (n=6), leg swelling (n=2), fatigue (n=2), diarrhea (n=1), abdominal pain (n=1). Two patients contracted COVID-19 during the study, both with mild symptoms, neither hospitalized. One patient had a serious adverse event during the study (transient thrombocytopenia attributed to concomitant use of antimicrobial therapy). Study outcomes are listed in Table 2. ESR and CRP were significantly lower at week 24 and week 52 compared to pre-enrollment values. Patient global assessment at week 0 was also significantly improved at both week 24 and week 52. Only 1 of 14 (7%) patients relapsed during the study (same patient at week 24 and week 52). The remaining 13 patients achieved steroid discontinuation and remained in disease remission during the duration of the 52-week study. Among patients completing the study, 4/14 (29%) flared during the 12-week follow up period after baricitinib discontinuation. Conclusion: In this proof of concept study, baricitinib at a dose of 4mg/day appeared both safe and effective in the management of patients with relapsing GCA. Larger randomized clinical trials are needed to determine the utility of JAK inhibition in GCA. Disclosures: KW received funds from Eli Lilly and Company to assist in the completion of the clinical trial. MK, CS, RG, JJ, EM, AD-G, CW report no financial disclosures of interest related to this study.

  • Other research product . Other ORP type . 2020
    Closed Access

    Ein kurzer Praxisbericht von heute und morgen Forscherinnen und Forscher sind eigenverantwortlich für die Einhaltung der guten wissenschaftlichen Praxis. Die Universitätsbibliothek Hildesheim begegnet ihnen im Forschungsdatenmanagement. Für die fortlaufende Unterstützung und Information zum Forschungsdatenmanagement (FDM) sind seit Beginn der Covid-19 Pandemie einfach vorhandene Formate für den digitalen Raum neu geformt worden. Der Support zum Datenmanagement wird vom Homeoffice aus geleistet. Es findet ständig Kontakt und Austausch mit den Forschenden statt, online mehr als früher vor Ort. Die Services sind geprägt durch Unterstützung bei der Erstellung von Datenmanagementplänen (RDMO). Forschungsnahe Services beschäftigen sich mit der Datenvielfalt, mit Karten, Texten, audiovisuellen Materialien, Fotosammlungen und Forschungssoftware, um nur einige Beispiele zu nennen. Hinzugekommen sind Beratungen im Bereich der Metadaten und fachspezifischen Metadatenschemata. Fragen sind immer auch, ob es rechtliche und ethische Hindernisse gibt, um Forschungsdaten zugänglich zu machen. Wie ist definiert, welche Daten aufbewahrt werden sollten und welche nicht.

  • Open Access Spanish
    Authors: 
    MENDOZA SALINAS BRENDA KAREN;
    Publisher: Zenodo

    El espectro clínico de la infección por Dengue y el COVID-19 presenta gran similitud en relación a los eventos fisiopatológicos. Por ello el presente trabajo tiene por finalidad conocer las características clínicas y de laboratorio en pacientes pediátricos con coinfección por dengue y COVID-19, Hospital EsSalud III – Iquitos, 2020. Se realizó un estudio de tipo descriptivo en 57 pacientes atendidos. Concluyendo que los síntomas más frecuentes fueron la fiebre (100 %), cefalea (70,2 %), astenia (68,4 %), náuseas (66,7 %) y vómitos (64,9 %). En menor proporción se observa que los pacientes presentaron escalofríos (52,6 %) y dolor abdominal (42,1 %). La pérdida de olfato y de gusto presentaron menor frecuencia. El 64,9 % presentaron leucocitos < 4000 / mm3, mientras que solo el 1,8 % presentaron leucocitos > 10 000 / mm3. Respecto a los linfocitos se observa que el 64,9 % presentaron linfocitos < 1500 / mm3 y 1,8 % presentaron linfocitos > 4000 / mm3. Respecto a neutrófilos se observa que 64,9 % de pacientes presentaron neutrófilos < 2000 / mm3. El 29,8 % presentaron eosinófilos < 40 / mm3 y el resto valores de 40 a 500 / mm3. En cuanto a monocitos el 21 % presentó un valor < 200 / mm3, el 3,5 % presentaron un valor > 800 / mm3. El 17,5 % de los pacientes presentaron basófilos < 10 / mm3, el 63,2 % 10 a 100 / mm3 y el 19,3 % > 100 / mm3. Respecto al hematocrito, se observa que el 71,9 % de pacientes presentaron hematocrito de 35 a 48 % y el 28,1 % un hematocrito menor a 35 %, el 41 % presentaron hemoglobina <12 g/dL y solo el 10,3 % un valor > 14 g/dL. La mayoría de pacientes presentaron plaquetas < 150000 / mm3. Palabras clave: COVID-19, dengue

  • Open Access
    Authors: 
    Lin Chen;
    Publisher: Zenodo

    This repository contains the code used in our paper: Strategic COVID-19 vaccine distribution can simultaneously elevate social utility and equity.